Navigation Links
CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
Date:10/23/2008

PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, November 6, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Thursday, November 13, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 68392680.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic str
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Histogen, Inc., a regenerative ... of cells grown under simulated embryonic conditions, will ... candidate for melanoma during the 2015 Society of ... 6-9, 2015 in Atlanta, GA. , Histogen has ... soluble material with anti-oncologic properties, with potential benefit ...
(Date:5/6/2015)... The Remedy Group , the ... the specialty pharmacy industry, will be exhibiting, presenting, and ... Pharmacy Summit. The Summit will be held May 4-8, ... is the largest annual gathering for the specialty pharmacy ... pharmacy providers, pharma/biotech manufacturers, and payers, to learn more ...
(Date:5/5/2015)... Mass. , May 5, 2015  Blueprint ... closing of its initial public offering of 9,367,708 ... price of $18.00 per share, including shares of ... the underwriters of their option to purchase additional ... offering to Blueprint Medicines were approximately $168.6 million, before ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... the detection of foodborne pathogens,  today announced that Paul ... Merrill Lynch 2015 Health Care Conference on May 12 at ... the Wynn, Las Vegas NV. ... available through the investor relations section of Roka Bioscience,s website ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Laboratories,Inc., a global provider of medical, nutraceutical, consumer ... a letter from The,Nasdaq Stock Market informing the ... of the Company, and would suspend trading in ... business on Thursday, August,16, 2007. As previously ...
... in Number and Viability of Stem Cells Derived from ... BioLife,s Patented Preservation Media, BOTHELL, Wash., Aug. 17 ... developer and marketer of,proprietary hypothermic storage and cryopreservation media ... as the exclusive,supplier of preservation media to the New ...
... Mass., Aug. 17 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... approvable letter from the U.S. Food and Drug ... valrubicin for intravesical,instillation, is the only product approved ... carcinoma in situ (CIS) of the,urinary bladder. ...
Cached Biology Technology:Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... person takes a pill full of a potent and effective drug, ... where it is needed a waste of money and inconvenient ... is a treatment for a serious illness. Polymer chemists ... up to design a solution. Their research to identify, understand, ...
... 2011 Fukushima nuclear plant disaster will reach the shores of ... incident but is likely to be harmless according to new ... atmospheric radiation was detected on the US west coast within ... plume take considerably longer to travel the same distance., In ...
... MD. AUGUST 28, 2013A competition for a $5,000 prize ... member of the American Society for Cell Biology (ASCB) ... The ASCB Kaluza Prize supported by Beckman Coulter, Inc., ... German mathematician Theodor Kaluza (1885-1954), who is the namesake ...
Cached Biology News:Researchers develop novel polymer to help oral medications reach the bloodstream 2Researchers develop novel polymer to help oral medications reach the bloodstream 3Researchers develop novel polymer to help oral medications reach the bloodstream 4Researchers develop novel polymer to help oral medications reach the bloodstream 5Fukushima radioactive plume to reach US in 3 years 2New ASCB Kaluza Prize recognizes graduate student research 2